CN111264851A - PWS syndrome targeted substitute health food and preparation method thereof - Google Patents
PWS syndrome targeted substitute health food and preparation method thereof Download PDFInfo
- Publication number
- CN111264851A CN111264851A CN202010139524.4A CN202010139524A CN111264851A CN 111264851 A CN111264851 A CN 111264851A CN 202010139524 A CN202010139524 A CN 202010139524A CN 111264851 A CN111264851 A CN 111264851A
- Authority
- CN
- China
- Prior art keywords
- parts
- pws
- weight
- powder
- health food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 15
- 235000013402 health food Nutrition 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 239000000843 powder Substances 0.000 claims abstract description 23
- 241000206607 Porphyra umbilicalis Species 0.000 claims abstract description 11
- 241001261506 Undaria pinnatifida Species 0.000 claims abstract description 11
- 229920001202 Inulin Polymers 0.000 claims abstract description 10
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 10
- 229940029339 inulin Drugs 0.000 claims abstract description 10
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 8
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 8
- 244000203593 Piper nigrum Species 0.000 claims abstract description 8
- 235000008184 Piper nigrum Nutrition 0.000 claims abstract description 8
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 8
- 235000008390 olive oil Nutrition 0.000 claims abstract description 8
- 239000004006 olive oil Substances 0.000 claims abstract description 8
- 235000013976 turmeric Nutrition 0.000 claims abstract description 8
- 240000002234 Allium sativum Species 0.000 claims abstract description 7
- 235000002566 Capsicum Nutrition 0.000 claims abstract description 7
- 244000304337 Cuminum cyminum Species 0.000 claims abstract description 7
- 235000007129 Cuminum cyminum Nutrition 0.000 claims abstract description 7
- 239000006002 Pepper Substances 0.000 claims abstract description 7
- 235000016761 Piper aduncum Nutrition 0.000 claims abstract description 7
- 235000017804 Piper guineense Nutrition 0.000 claims abstract description 7
- 235000004611 garlic Nutrition 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 235000011844 whole wheat flour Nutrition 0.000 claims abstract description 7
- 235000002568 Capsicum frutescens Nutrition 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 17
- 240000004160 Capsicum annuum Species 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 21
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 10
- 208000032841 Bulimia Diseases 0.000 abstract description 8
- 206010006550 Bulimia nervosa Diseases 0.000 abstract description 8
- 235000005686 eating Nutrition 0.000 abstract description 8
- 230000002503 metabolic effect Effects 0.000 abstract description 7
- 208000024891 symptom Diseases 0.000 abstract description 5
- 230000036186 satiety Effects 0.000 abstract description 4
- 235000019627 satiety Nutrition 0.000 abstract description 4
- 208000031964 Other metabolic disease Diseases 0.000 abstract description 3
- 235000004280 healthy diet Nutrition 0.000 abstract description 3
- 241001474374 Blennius Species 0.000 description 22
- 239000000047 product Substances 0.000 description 17
- 208000008589 Obesity Diseases 0.000 description 9
- 235000020824 obesity Nutrition 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 230000037213 diet Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000002411 adverse Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 208000030159 metabolic disease Diseases 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000009578 growth hormone therapy Methods 0.000 description 3
- 235000013406 prebiotics Nutrition 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- SJWWTRQNNRNTPU-ABBNZJFMSA-N fucoxanthin Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]1(C(C[C@H](O)C2)(C)C)[C@]2(C)O1 SJWWTRQNNRNTPU-ABBNZJFMSA-N 0.000 description 2
- AQLRNQCFQNNMJA-UHFFFAOYSA-N fucoxanthin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC(=CC=CC=C(/C)C=CC=C(/C)C(=O)CC23OC2(C)CC(O)CC3(C)C)C)CO)C(C)(O)C1 AQLRNQCFQNNMJA-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108700021677 Agouti-Related Proteins 0.000 description 1
- 235000021411 American diet Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 229920000855 Fucoidan Polymers 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 description 1
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000002746 Inhibins Human genes 0.000 description 1
- 108010004250 Inhibins Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 102000002512 Orexin Human genes 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920001715 Porphyran Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 235000013614 black pepper Nutrition 0.000 description 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000034525 diet induced thermogenesis Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 235000021321 essential mineral Nutrition 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 235000021192 high fiber diet Nutrition 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 208000001022 morbid obesity Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 108060005714 orexin Proteins 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000035924 thermogenesis Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/60—Edible seaweed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/198—Dry unshaped finely divided cereal products, not provided for in groups A23L7/117 - A23L7/196 and A23L29/00, e.g. meal, flour, powder, dried cereal creams or extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Food Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Botany (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a PWS syndrome targeted substitute health food and a preparation method thereof, wherein the PWS syndrome targeted substitute health food is prepared from the following raw materials in parts by weight: 300 parts of wholewheat flour, 5-8 parts of garlic pods, 15 parts of cumin seeds, 15 parts of pepper powder, 1 part of turmeric powder, 2 parts of chili powder, 2 parts of olive oil, 10 parts of edible salt, 100 parts of undaria pinnatifida, 100 parts of laver and 59 parts of inulin; the product can make PWS children obtain a healthy metabolic state. The product can effectively control the bulimia symptoms by producing satiety. The clinical significance of the product as a daily healthy diet regular for eating on other metabolic diseases including type 2 diabetes and insulin resistance is obtained through comparison.
Description
Technical Field
The invention relates to the field of health-care food, in particular to PWS syndrome targeted substitute health-care food and a preparation method thereof.
Background
Prader-willi syndrome, called PWS for short, is a hereditary metabolic disease affecting the health of teenagers and children. The genetic types of PWS are several: chromosomal variation at positions 15q11-q 13: deletions of most type 1 and a small portion of type 2 parental chromosomes; a microdeletion; gene imprinting; maternal homologous diploids. Children with these genetic variations present with typical clinical symptoms in infancy, including: low muscle tone (0-9 months), excessive appetite (bulimia beginning at 4.5-8 years), psychological disorders such as skin scratching, insufficient mood control, sleep apnea, increased fat, early obesity in children, loss of body fat and weight, type 2 diabetes, insulin resistance, delayed sexual and growth development, insufficient cognitive ability, respiratory diseases, high pain threshold, and osteoporosis.
Although the application of growth hormone (1.0 mg/kg/week) has significant effects on improving the growth, body fat free weight increase and Body Mass Index (BMI) reduction of PWS children, it does not improve the adverse clinical manifestations and the current situation of increased early mortality of PWS children. In addition, the application time of growth hormone therapy is limited, and the growth hormone therapy is generally not applied any more after the children patients reach normal height, which suggests the limitation of growth hormone therapy. The average life expectancy of PWS infants is currently between 35 and 40 years of age, and continued bulimia eventually worsens their health and early mortality, possibly due to increased fat mass and altered gut flora that affects the incidence of type 2 diabetes and insulin resistance in the early stages of PWS development. It is imperative to improve the lifestyle and life expectancy of children suffering from PWS. We have found that lifestyle changes, particularly healthy eating, may be an effective treatment for managing adverse syndrome caused by bulimia in PWS in children. Early studies found that prebiotic diets containing inulin and fructo-oligosaccharides produced effective therapeutic effects on PWS children. Studies have shown that energy expenditure in infants suffering from PWS is reduced in various activities such as sleeping, eating, walking, resting. Eating a high protein, high fiber diet can effectively control the adverse clinical symptoms associated with the bulimia of children suffering from PWS, as a result of satiety and improved thermogenesis of food and beneficial gut flora. Similar to prebiotics, dietary seaweed rich in nutrients contains higher protein, fiber, omega-3 fatty acids, polyphenols, carotenes, and has been shown to reverse metabolic-related disorders including obesity, type 2 diabetes, and insulin resistance.
Therefore, the PWS syndrome targeted substitute health food and the preparation method thereof are provided, and the PWS syndrome targeted substitute health food has wide market prospect.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides a PWS syndrome targeted substitute health food and a preparation method thereof, which are used for overcoming the defects in the prior art.
The technical scheme of the invention is realized as follows: a PWS syndrome targeted substitute health food is prepared from the following raw materials in parts by weight: 300 parts of wholewheat flour, 5-8 parts of garlic pods, 15 parts of cumin seeds, 15 parts of pepper powder, 1 part of turmeric powder, 2 parts of chili powder, 2 parts of olive oil, 10 parts of edible salt, 100 parts of undaria pinnatifida, 100 parts of laver and 59 parts of inulin.
The preparation method of the PWS syndrome targeted substitute health food comprises the following steps: firstly, mixing and uniformly crushing the undaria pinnatifida and the laver in parts by weight, then adding the garlic pods in parts by weight into a mixed material, mixing and uniformly crushing the mixture again to obtain a primary mixture, then uniformly stirring and mixing the primary mixture and the inulin in parts by weight by using the olive oil in parts by weight to obtain a middle-grade mixture, adding the wholewheat flour, the cumin seeds, the pepper powder, the turmeric powder, the chilli powder and the edible salt in parts by weight into the middle-grade mixture to obtain a final mixed dough, then slightly flattening the dough by using a tool, cutting the flattened dough by using a cutting device, and finally frying the cut dough by using an air frying machine to dry, thus obtaining the finished product.
The invention has the following positive effects: the product can make PWS children obtain a healthy metabolic state. The product can effectively control the bulimia symptoms by producing satiety. The clinical significance of the product as a daily healthy diet regular for eating on other metabolic diseases including type 2 diabetes and insulin resistance is obtained through comparison.
Detailed Description
A PWS syndrome targeted substitute health food is prepared from the following raw materials in parts by weight: 300 parts of wholewheat flour, 5-8 parts of garlic pods, 15 parts of cumin seeds, 15 parts of pepper powder, 1 part of turmeric powder, 2 parts of chili powder, 2 parts of olive oil, 10 parts of edible salt, 100 parts of undaria pinnatifida, 100 parts of laver and 59 parts of inulin.
The preparation method of the PWS syndrome targeted substitute health food comprises the following steps: firstly, mixing and uniformly crushing the undaria pinnatifida and the laver in parts by weight, then adding the garlic pods in parts by weight into a mixed material, mixing and uniformly crushing the mixture again to obtain a primary mixture, then uniformly stirring and mixing the primary mixture and the inulin in parts by weight by using the olive oil in parts by weight to obtain a middle-grade mixture, adding the wholewheat flour, the cumin seeds, the pepper powder, the turmeric powder, the chilli powder and the edible salt in parts by weight into the middle-grade mixture to obtain a final mixed dough, then slightly flattening the dough by using a tool, cutting the flattened dough by using a cutting device, and finally frying the cut dough by using an air frying machine to dry, thus obtaining the finished product.
When in specific use, the product is intended to be applied to PWS children patients of 4.5-8 years old to intervene in eating-related adverse metabolic diseases, including obesity, type 2 diabetes and insulin resistance. Study to recruit 15-20 PWS children aged between 4.5-8 years as study subjects in the children's hospital endocrine-metabolics department of Henan province. Subjects were excluded from the following cases: severe respiratory diseases, cardiovascular complications, severe obesity, osteoporosis and other psychobehavioral disorders. Meanwhile, 15-20 normal healthy children and simply obese children of the same age group were included as control groups for PWS children to observe clinical changes in diet prognosis. The control group of children were excluded: there is an early record of any food allergies, severe respiratory infections, cardiovascular complications.
Before intervention, an enzyme-linked immunosorbent assay is used for detecting clinical protein biological indexes related to the bulimia and the intestinal tract structure function, wherein the related indexes are as follows: adiponectin, leptin, insulin, ghrelin, polypeptide YY, orexin, brain-derived neurotrophic factor, pancreatic polypeptide, agouti-related peptide, cholecystokinin, neuropeptide, obesity inhibin, glucagon-like peptide-1, glucagon-like peptide-2. The level of serum lipopolysaccharide in the circulation is measured to assess the degree of metabolic endotoxemia. The faecal intestinal flora profile, in particular the intestinal beneficial flora profile, will be fully evaluated in the study. Based on a basic understanding of these clinical variables, the product will be applied to PWS children and two other groups of children for 1 year of dietary intervention. During study intervention, all study participants were required to follow a healthy american diet pattern. The above-mentioned established clinical indexes need to be tested 1 time every 3 months for 1 year to evaluate the treatment effect of the product. The subjects in the study required three meals a day before the product, totaling 100g in one day. The PWS infant guardian needs to take the product for eating when the infant patient requires to eat.
The research shows that the product can effectively control the bulimia symptoms by generating satiety. In addition, the carotenoid with therapeutic effect in the product: fucoxanthin can improve intestinal flora of PWS children, increase energy consumption, and especially improve diet-induced thermogenesis, so as to promote PWS children to obtain a healthy metabolic state. By comparing the expected results of the PWS infant group with the other two groups (normal control group and simple obesity group), we can obtain the clinical significance of the product as a daily healthy diet regular food intake for other metabolic diseases including type 2 diabetes and insulin resistance. Based on the expected results of the above studies, PWS children and other study participants were recommended to use the product as a daily diet to achieve a metabolically healthier lifestyle.
Seaweed has been widely documented in research as a therapeutic diet. Supplement of seaweed can relieve obesity, hypertension, type 2 diabetes, and metabolic diseases related to insulin resistance. The therapeutic effect of seaweeds benefits from the fact that they contain high nutritional ingredients such as polysaccharides, polyphenols, trace elements, vitamins, proteins, and low fat, thereby helping the human body to establish a stable and healthy lifestyle, and japanese people eat seaweeds as a daily diet: 5.3-10 g/day, although China is the largest producing and exporting country of seaweed, Chinese people eat seaweed less as much as the western population. Therefore, the prevalence of metabolic-related diseases in chinese, such as obesity, type 2 diabetes, insulin resistance, is at the highest level, which is associated with their western diet.
The product is intended to apply two commonly used seaweeds: undaria pinnatifida and laver in the form of crisp chips are used as snacks for PWS children. The two seaweeds are widely consumed in south korea because of their high nutritive value and bioactive factors having the effect of reducing metabolic complications such as fucoxanthin and fucoidan in undaria pinnatifida, and porphyran in laver. Laver contains a higher protein fraction (33.2% of the dried seaweed) than undaria pinnatifida, and is rich in all essential amino acids including phenylalanine, tyrosine, threonine, arginine, glycine, aspartic acid and vitamin a (23, 830 ± 17.2 UI/kg). Undaria pinnatifida is a reliable source of dietary protein (16.8% of dry seaweed), contains all essential amino acids, contains higher dietary fiber (between 14.9% and 28.3% of dry seaweed) and essential mineral ions such as: calcium (693.2 mg/100g dry seaweed), phosphorus (1070 mg/100g dry seaweed), sodium (3511 mg/100g dry seaweed), magnesium (630.2 mg/100g dry seaweed) and potassium (5679 mg/100g dry seaweed). Both seaweeds were low in fat (1% -2.8% of dry seaweed) and had levels of monounsaturated and polyunsaturated fatty acids far above those of saturated fatty acids in total fat content. In addition, the laver contains dietary fiber in an amount of 7.8% of the dried seaweed. Recognizing the therapeutic effects of eating these seaweeds on metabolic diseases, especially obesity, type 2 diabetes, insulin resistance, hypertension, we believe that seaweed and further inulin supplementation: the fructo-oligosaccharide mixture can improve the therapeutic effect of the product. Inulin: fructooligosaccharides as a prebiotic mixture have great health benefits and are therefore recommended as a functional diet for humans to improve metabolic disorders. Besides improving beneficial intestinal flora (such as Bifidobacterium, Bacteroides, Streptococcus and lactic acid), it also has strong therapeutic effects on inflammatory bowel disease, osteoporosis, obesity, type 2 diabetes, and intestinal structural and functional injury. Furthermore, in order to make the product have a crisp taste and thereby increase the edibility of PWS children, we have added other food ingredients such as: olive oil, black pepper, chili powder, turmeric powder and the like. The addition of these food ingredients is based on the careful addition of nutritional value while complying with mediterranean dietary habits that are standard in a healthy lifestyle.
Claims (2)
1. The PWS syndrome targeted substitute health food is characterized by being prepared from the following raw materials in parts by weight: 300 parts of wholewheat flour, 5-8 parts of garlic pods, 15 parts of cumin seeds, 15 parts of pepper powder, 1 part of turmeric powder, 2 parts of chili powder, 2 parts of olive oil, 10 parts of edible salt, 100 parts of undaria pinnatifida, 100 parts of laver and 59 parts of inulin.
2. The preparation method of the PWS syndrome targeted substitute health food of claim 1, comprising the steps of: firstly, mixing and uniformly crushing the undaria pinnatifida and the laver in parts by weight, then adding the garlic pods in parts by weight into a mixed material, mixing and uniformly crushing the mixture again to obtain a primary mixture, then uniformly stirring and mixing the primary mixture and the inulin in parts by weight by using the olive oil in parts by weight to obtain a middle-grade mixture, adding the wholewheat flour, the cumin seeds, the pepper powder, the turmeric powder, the chilli powder and the edible salt in parts by weight into the middle-grade mixture to obtain a final mixed dough, then slightly flattening the dough by using a tool, cutting the flattened dough by using a cutting device, and finally frying the cut dough by using an air frying machine to dry, thus obtaining the finished product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010139524.4A CN111264851A (en) | 2020-03-03 | 2020-03-03 | PWS syndrome targeted substitute health food and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010139524.4A CN111264851A (en) | 2020-03-03 | 2020-03-03 | PWS syndrome targeted substitute health food and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111264851A true CN111264851A (en) | 2020-06-12 |
Family
ID=70991632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010139524.4A Pending CN111264851A (en) | 2020-03-03 | 2020-03-03 | PWS syndrome targeted substitute health food and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111264851A (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000344673A (en) * | 1999-05-31 | 2000-12-12 | Nippon Flour Mills Co Ltd | Fat accumulation inhibitor, anti-obesity agent, food additive, food and pet food |
| US20050003026A1 (en) * | 2002-08-14 | 2005-01-06 | Song-Hae Bok | Powder or extracts of plant leaves with anti-obesity effects and anti-obesity food comprising them |
| US20080206275A1 (en) * | 2006-12-08 | 2008-08-28 | Zakir Ramazanov | Composition for treating obesity and method of using the same |
| US20080233209A1 (en) * | 2007-03-22 | 2008-09-25 | Polifenoles Naturales, Sl | Composition and method of use for the treatment of metabolic syndrome and inflammation |
| US20100093847A1 (en) * | 2005-05-24 | 2010-04-15 | Kazuo Miyashita | Anti-obesity active agent and anti-obesity method |
| CN101721403A (en) * | 2008-10-16 | 2010-06-09 | 北京绿色金可生物技术股份有限公司 | Application of fucoxanthin in aspect of losing weight |
| CN106310006A (en) * | 2015-06-30 | 2017-01-11 | 完美（中国）有限公司 | Application of the combination package in the preparation of food, medicine, health products and nutritional products for improving and treating human chubby-Willi syndrome |
| CN109562092A (en) * | 2016-06-03 | 2019-04-02 | 纽约市哥伦比亚大学理事会 | Treat pula moral-Willie syndrome method |
-
2020
- 2020-03-03 CN CN202010139524.4A patent/CN111264851A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000344673A (en) * | 1999-05-31 | 2000-12-12 | Nippon Flour Mills Co Ltd | Fat accumulation inhibitor, anti-obesity agent, food additive, food and pet food |
| US20050003026A1 (en) * | 2002-08-14 | 2005-01-06 | Song-Hae Bok | Powder or extracts of plant leaves with anti-obesity effects and anti-obesity food comprising them |
| US20100093847A1 (en) * | 2005-05-24 | 2010-04-15 | Kazuo Miyashita | Anti-obesity active agent and anti-obesity method |
| US20080206275A1 (en) * | 2006-12-08 | 2008-08-28 | Zakir Ramazanov | Composition for treating obesity and method of using the same |
| US20080233209A1 (en) * | 2007-03-22 | 2008-09-25 | Polifenoles Naturales, Sl | Composition and method of use for the treatment of metabolic syndrome and inflammation |
| CN101721403A (en) * | 2008-10-16 | 2010-06-09 | 北京绿色金可生物技术股份有限公司 | Application of fucoxanthin in aspect of losing weight |
| CN106310006A (en) * | 2015-06-30 | 2017-01-11 | 完美（中国）有限公司 | Application of the combination package in the preparation of food, medicine, health products and nutritional products for improving and treating human chubby-Willi syndrome |
| CN109562092A (en) * | 2016-06-03 | 2019-04-02 | 纽约市哥伦比亚大学理事会 | Treat pula moral-Willie syndrome method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hollis | The effect of mastication on food intake, satiety and body weight | |
| JP3647042B2 (en) | Cereal foods rich in soluble fiber | |
| CN102308941B (en) | Diet green coarse cereal food and preparation method thereof | |
| CN101288466A (en) | Stuffed mushroom cake and preparation method thereof | |
| EP1259112A1 (en) | Nutritional intervention composition for enhancing and extending satiety | |
| JP2004515508A (en) | COMPOUND HEALTH PROMOTING COMPOSITION | |
| US20170173099A1 (en) | Compositions and Methods for Increasing the Suppression of Hunger and Reducing the Digestibility of Non-Fat Energy Satiety | |
| JP2013010762A (en) | Starch subtype and lipid metabolism | |
| CN107006781B (en) | A kind of food rich in dietary fiber that can delay the rise of blood sugar and processing method thereof | |
| CN111165721A (en) | Staple food powder containing low net carbohydrate and high dietary fiber | |
| Matsuoka et al. | Consumption of a meal containing refined barley flour bread is associated with a lower postprandial blood glucose concentration after a second meal compared with one containing refined wheat flour bread in healthy Japanese: a randomized control trial | |
| EP3263118A1 (en) | Flaxseeds for body weight management | |
| EP2076256B1 (en) | Meal replacement compositions and weight control method | |
| Caferoglu et al. | Effects of whole-grain barley and oat β-glucans on postprandial glycemia and appetite: a randomized controlled crossover trial | |
| CN105361125A (en) | Snacks having health-caring function | |
| CN1857117A (en) | Composite powder for balancing human body energy metabolism | |
| CN108514090A (en) | It is a kind of using banana as weight losing meal-replacing stick of primary raw material and preparation method thereof | |
| US6455095B2 (en) | Thermogenic, appetite suppressing, gas suppressing, complete legume protein formulae; thermobean™ | |
| CN109997894A (en) | A kind of low-glycemic blueberry rice bran department health cake and its preparation method and application | |
| Suzuki et al. | Effect of dietary fiber-enriched brown rice crackers on suppressing elevation of blood glucose level | |
| CN108378296A (en) | Peri-operation period nutraceutical | |
| CN111264851A (en) | PWS syndrome targeted substitute health food and preparation method thereof | |
| CN112369448A (en) | Low-GI biscuit and preparation method thereof | |
| CN116019193A (en) | 3D printing food material, manufacturing method thereof and 3D printing food | |
| WO2018113376A1 (en) | Diet food for liver stasis-type obesity and use and preparation process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200612 |